Opinion|Videos|January 31, 2025

Patient Selection for Aflibercept 8 mg

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.

Video content above is prompted by the following:

  • Who is the ideal patient for aflibercept 8 mg?

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME